Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...